Insights

Gathering insights about NRB…

Similar companies to NRB

NRB Tech Stack

NRB uses 8 technology products and services including LinkedIn Ads, Fastly, Priority Hints, and more. Explore NRB's tech stack below.

LinkedIn Ads
Advertising
Fastly
Content Delivery Network
Priority Hints
Performance
UltimatelySocial
Social Sharing
Vimeo
Video Players
Google Analytics
Web Analytics
easy pie chart
Web Tools And Plugins
FlexSlider
Widgets

Media & News

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass. , Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date").
Nov 18, 2024 | www.prnewswire.com
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum.
Nov 13, 2024 | www.prnewswire.com
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at End of Third Quarter E xpected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass. , Nov. 7, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Nov 07, 2024 | www.prnewswire.com
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Topline Data Readout From Part 1 and Part 2 Expected in December 2024 CAMBRIDGE, Mass. , Nov. 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Nov 04, 2024 | www.prnewswire.com
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
CAMBRIDGE, Mass. , Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: October 7: H.C.
Oct 01, 2024 | www.prnewswire.com
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Sep 30, 2024 | www.prnewswire.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Mass. , Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
Sep 03, 2024 | www.prnewswire.com

NRB's Email Address Formats

NRB uses at least 1 format(s):

NRB Email Formats	Example	Percentage
FLast@nrb.org	JDoe@nrb.org	71%
Last@nrb.org	Doe@nrb.org	14%
First@nrb.org	John@nrb.org	12%
FirstLast@nrb.org	JohnDoe@nrb.org	3%

Frequently Asked Questions

Where is NRB's headquarters located?

NRB's main headquarters is located at P/o Box 77704 Suite 210 Washington, District of Columbia 20001 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is NRB's phone number?

You can contact NRB's main corporate office by phone at

+1-703-330-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is NRB's stock symbol?

NRB is a publicly traded company; the company's stock symbol is NRBO.

What is NRB's official website and social media links?

NRB's official website is nrb.org and has social profiles on LinkedIn.

How much revenue does NRB generate?

As of February 2026, NRB's annual revenue is estimated to be $3.5M.

What is NRB's SIC code NAICS code?

NRB's SIC code is 8611 - Business Associations NAICS code is 515 - Broadcasting (except Internet).

How many employees does NRB have currently?

As of February 2026, NRB has approximately 47 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Of Staff: B. E.Vice President Of Membership And Events: B. W.Vp Of Finance: M. K.. Explore NRB's employee directory with LeadIQ.

What industry does NRB belong to?

NRB operates in the Broadcast Media Production and Distribution industry.

What technology does NRB use?

NRB's tech stack includes LinkedIn AdsFastlyPriority HintsUltimatelySocialVimeoGoogle Analyticseasy pie chartFlexSlider.

What is NRB's email format?

NRB's email format typically follows the pattern of FLast@nrb.org. Find more NRB email formats with LeadIQ.

When was NRB founded?

NRB was founded in 1944.

NRB

Q: What is NRB's official website and social media links?

NRB's official website is nrb.org. NRB has social profiles on LinkedIn.

Q: How many employees does NRB have currently?

NRB has approximately 47 employees.

Q: What technology does NRB use?

NRB's tech stack includes Fastly, Cloudflare, Google Tag Manager, SiteGround, WordPress.

Broadcast Media Production and DistributionDistrict of Columbia, United States11-50 Employees

NRB is the world's largest association of Christian communicators. Since 1944, we have worked to protect free speech and foster excellence in communication.

Company Overview

Headquarters: P/o Box 77704 Suite 210 Washington, District of Columbia 20001 United States
Phone number: +1-703-330-****
Website: nrb.org
SIC Code: 8611 - Business Associations
Stock Symbol: NRBO
NAICS Code: 515 - Broadcasting (except Internet)
Founded: 1944
Employees: 11-50

Media & News

Funding & Financials

$25M$50M
NRB's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$25M$50M
NRB's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to NRB

Radio Television Digital News Association (RTDNA)

Poynter Institute

NRB Tech Stack

Media & News

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NRB's Email Address Formats

Frequently Asked Questions

Where is NRB's headquarters located?

What is NRB's phone number?

What is NRB's stock symbol?

What is NRB's official website and social media links?

How much revenue does NRB generate?

What is NRB's SIC code NAICS code?

How many employees does NRB have currently?

What industry does NRB belong to?

What technology does NRB use?

What is NRB's email format?

When was NRB founded?

NRB

Company Overview

Media & News

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?